# Zymeworks Inc.

Zymeworks Inc. is an other based in Vancouver, Canada.

## Overview

- **Organization type:** other
- **Headquarters:** Vancouver, Canada
- **Region:** North America
- **Address:** Vancouver, British Columbia, Canada
- **Founded:** 2003
- **Assets under management:** Undisclosed
- **Website:** www.zymeworks.com
- **LinkedIn:** https://www.linkedin.com/company/zymeworks

## Regulatory record

- **Reports private funds:** No

## About

Zymeworks develops novel medicines for patients with difficult-to-treat cancers and other serious diseases, focusing on biologics drug discovery and development, including antibody-based therapeutics and bispecific antibodies. The company has a team of experienced leaders and researchers, including a Chief Scientific Officer with over 25 years of experience in biotechnology research. Zymeworks is working on various treatments, including those for cancers and autoimmune conditions.

## Sectors

- Biotech & Pharma
- Oncology

## People

- Kenneth A. Galbraith — Chief Executive Officer
- Neil A. Klompas — President and Chief Operating Officer
- Shane C. M. Campbell — Chief Business Officer

## Questions

### Who runs investment decisions at Zymeworks?

As a publicly traded company, Zymeworks' board of directors oversees corporate strategy, while CEO Kenneth Galbraith leads executive decisions. The scientific direction is shaped by the founding team and chief scientific officer.

### How does Zymeworks source its proprietary technology?

Zymeworks developed its bispecific antibody platform internally over two decades. The Azymetric platform is its core intellectual property, enabling precise engineering of antibodies that can bind two targets simultaneously.

### Does Zymeworks participate in fund commitments or only direct deals?

Zymeworks is an operating biotech company; it does not deploy capital as an investment manager. Its partnerships with Jazz Pharmaceuticals and Daiichi Sankyo involve upfront payments, equity investments, and milestone revenues.

### Which investment stages does Zymeworks typically target?

Zymeworks focuses on preclinical and clinical-stage drug development. It advances its own pipeline to early-phase clinical trials before seeking partners for late-stage development and commercialization.

### What investment sectors does Zymeworks explicitly avoid?

Zymeworks concentrates exclusively on oncology and immuno-oncology. It does not engage in other therapeutic areas such as neurology, infectious disease, or rare diseases.

### How is Zymeworks related to other entities?

Zymeworks is a standalone public company (NYSE: ZYME). It has subsidiary operations in the U.S. through Zymeworks USA Inc. and historically had a collaboration with Eli Lilly, which was terminated.

## Related profiles

- [LakePharma](https://altss.com/profile/lakepharma)
- [Friesens Corp](https://altss.com/profile/friesens-corp)

---

Last updated: 2026-07-10T13:16:51.000Z

Canonical page: https://altss.com/profile/zymeworks-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology